<DOC>
	<DOCNO>NCT01758029</DOCNO>
	<brief_summary>This study conduct prospective , single-center ( multiple clinic ) , single-arm open phase IV study . study follow hypogonadal patient , aim confirm hypothesis testosterone undecanoate improves patient satisfaction quality life , parallel improvement spouse 's quality life satisfaction . Each patient/spouse serve control .</brief_summary>
	<brief_title>Testosterone Undecanoate Quality Life Men Spouses</brief_title>
	<detailed_description>study protocol follow hypogonadal patient , initiate treatment testosterone undecanoate , give accordance standard protocol . Hypogonadal men eligible treatment testosterone undecanoate , treat testosterone undecanoate within last 6 month prior enrollment , enrol study . Patients treat another testosterone formulation ( eg . testosterone gel , testosterone enanthate injection ) require 4 week wash-out period . Patients must enrol decision treatment testosterone undecanoate make . Patients follow observation period 28 week . Observations record 3 consecutive visit , assess patient spouse satisfaction quality life validate questionnaire . The study design intra-individual comparison . Each patient/spouse serve control . laboratory test total testosterone level require last visit . need concomitant phosphodiesterase-5 inhibitor use also record analyze .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Hypogonadal patient age 40 80 newly prescribe testosterone undecanoate . The patient must stable ( &gt; 3 month ) heterosexual relationship eligible study Diagnosis hypogonadism discretion physician , base patient 's symptom laboratory evidence T level 12 ( symptomatic patient borderline level 8.4 12 also eligible testosterone replacement therapy ) Washout 6 month testosterone undecanoate , 4 week testosterone formulation , study entry . Patient &amp; spouse must capable willing fillin questionnaire enrol study Informed consent require The standard contraindication warning treatment testosterone replacement therapy , specifically testosterone undecanoate , must follow . Contraindications copy product prescribe information : androgendependent carcinoma prostate male mammary gland ; past present liver tumor ; hypersensitivity active substance excipients Men desire paternity exclude</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>quality life</keyword>
	<keyword>Testosterone Undecanoate</keyword>
	<keyword>partner</keyword>
	<keyword>questionnaire</keyword>
</DOC>